Previous Article | Next Article 
Journal of Virology, January 2001, p. 952-960, Vol. 75, No. 2
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.2.952-960.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Coxsackievirus A9 VP1 Mutants with Enhanced or
Hindered A Particle Formation and Decreased Infectivity
Antero
Airaksinen,*
Merja
Roivainen, and
Tapani
Hovi
Enterovirus Laboratory, National Public
Health Institute (KTL), FIN-00300 Helsinki, Finland
Received 8 May 2000/Accepted 16 October 2000
 |
ABSTRACT |
We have studied coxsackievirus A9 (CAV9) mutants that each have a
single amino acid substitution in the conserved 29-PALTAVETGHT-39 motif
of VP1 and a reduced capacity to produce infectious progeny virus.
After uncoating, all steps in the infection cycle occurred according to
the same kinetics as and similar efficiency to the wild-type virus.
However, the particle/infectious unit ratio in the progeny was
significantly increased. The differences were apparently due to altered
stability of the capsid: there were mutant viruses with enhanced or
hindered uncoating, and both of these characteristics were found to
reduce fitness under standard passaging conditions. At 32°C the
instable mutants had an advantage, while the wild-type and the most
stable mutant grew poorly. When comparing the newly published CAV9
structure and the other enterovirus structures, we found that the
PALTAVETGHT motif is always in exactly the same position, in a cavity
formed by the 3 other capsid proteins, with the C terminus of VP4
between this motif and the RNA. In the 7 enterovirus structures
determined to date, the most conserved residues of the studied motif
have identical contacts to neighboring residues of VP2, VP3, and VP4.
We conclude that (i) the mutations affect the uncoating step necessary
for infection, resulting in an untimely or hindered externalization of
the VP1 N terminus together with the VP4, and (ii) the reason for the
studied motif being evolutionarily conserved is its role in maintaining
an optimal balance between the protective stability and the functional
flexibility of the capsid.
 |
INTRODUCTION |
Coxsackievirus A9 (CAV9)
is a member of the Enterovirus genus in the family
Picornaviridae. Enteroviruses have icosahedral capsids that
consist of 60 copies of each of the four capsid proteins VP1 to VP4.
Their genomes are single molecules of positive-stranded RNA,
approximately 7,500 nucleotides in length.
In order to initiate a new infection cycle, enteroviruses have to
attach to the host cell, uncoat to reveal the RNA, and at least the RNA
must cross a membrane to enter the cell cytoplasm. For CAV9 there are
at least two alternative receptors, the integrin
v
3 (25, 27), and an
unidentified cell surface receptor (17, 28). Several other
specific receptors are known for various enteroviruses, but the
mechanism and location of crossing the membrane are still unclear. It
is known that the A particles, altered virus particles lacking the VP4
and having the N terminus of VP1 externalized, of poliovirus type 1 (PV1) are capable of binding to liposomes through the N terminus of VP1
(12). Furthermore, A particles as well as native
polioviruses induce channel formation in an artificial membrane
(30). The N terminus of VP1 might thus form a pore
structure in one of the cell membranes, possibly together with VP4,
allowing the RNA to be externalized from the capsid and enter the
cytoplasm (12). The pseudoatomic models of the poliovirus
135S and 80S particles were recently determined by cryo-electron
microscopy and image reconstruction (5). Based on these
structures, the model was revised to include a possible "float
valve" in the form of the VP3 plug that was found to be at the
fivefold axis in the 135S particle as well as in the 160S particle.
The N terminus of VP1 has been shown to be reversibly externalized from
the capsid, being recognized in the native poliovirus by peptide
antibodies (26). It has also been reported that
unidentified parts of VP4 are similarly recognized by antibodies, but
only when coincubating the poliovirus and antisera at 37°C
(20). This dynamic nature of the capsid also explains the
temperature-dependent formation of channels upon incubating native
poliovirus with artificial lipid bilayers (30). The
mechanisms of these transient modifications are still not known.
Likewise, the location of externalization of the VP4 and the N terminus
of VP1 still remains open. Two recent studies give support to two
different models, assuming externalization to occur either near the
base of the canyon, judging by the structures of the poliovirus 135S
and 80S particles (5), or through the fivefold axis, as
judged on the basis of the CAV9 structure (14).
In order to gain more understanding about the uncoating process of
enteroviruses, we decided to study the effects of mutations in a highly
conserved motif of approximately 11 amino acids that is in the
externalized N terminus of the capsid protein VP1 in all enteroviruses
(16). This region contains several amino acids that were
found to be completely conserved in an alignment of 79 different
enterovirus sequences (2). Due to the strong conservation of the studied motif among enteroviruses, CAV9 can be considered to
serve here as a model virus: we presume that the CAV9 characteristics found in this study should reflect the properties of other
enteroviruses as well.
 |
MATERIALS AND METHODS |
Virus strains and cell cultures.
We have used CAV9 mutants
that were generated earlier (1, 2), originally derived
from an infectious cDNA clone obtained from Glyn Stanway (University of
Essex, Colchester, United Kingdom) (6, 17). The viruses
were propagated in the monkey kidney cell line LLC Mk2,
which was maintained in the minimal essential medium of Eagle,
supplemented with 10% fetal calf serum.
Buffers.
The following buffers, with compositions as
indicated, were used: phosphate-buffered saline (PBS), pH 7.3; DPBS,
PBS containing 1 mM MgCl2 and 1 mM CaCl2;
blocking buffer, PBS containing 2% bovine serum albumin (BSA), 30 mM
MgCl2, and 1 mM CaCl2; lysis buffer, 0.5 % Triton X-100 in DPBS containing 0.1% BSA; RSB, 10 mM Tris, 10 mM NaCl,
1.5 mM MgCl2 (pH 7.4); washing buffer 1, 1% Triton X-100
in Tris-HCl (pH 7.4), 5 mM EDTA, 500 mM NaCl, 5 mM sucrose; and washing
buffer 2, Tris-HCl (pH 6.8), 1 mM EDTA.
RNA purification, RT-PCR, and sequencing.
The whole capsid
coding region was sequenced from all viruses. The viral RNA was
purified using the Qiagen RNeasy kit (Qiagen Ltd., Crawley, West
Sussex, United Kingdom). Reverse transcriptase PCR (RT-PCR) was
performed by using either the RobusT RT-PCR kit (Finnzymes, Espoo,
Finland) or a combination of avian myeloblastosis virus reverse
transcriptase (Promega) and Dynazyme (Finnzymes). The amplicons were
sequenced with an ABI sequencer, using the PCR primers. The primers are
shown in Table 1.
Infection kinetics.
The kinetics of the production of
infectious virus was measured in 24-well plates of LLC Mk2
cells. The cells were infected with equal multiplicities of infection
(MOIs) of the various mutant viruses and the wild-type virus. The
inoculum was removed after incubating 1 h at room temperature. The
cells were washed twice and covered with 1 ml of medium containing 1%
fetal calf serum. The infection was allowed to proceed at 37°C, and
the cells were scraped from two wells of each virus at 2-h intervals.
The cells were freeze-thawed three times together with the medium, and
cell debris was removed by centrifuging 10 min in an Eppendorf
centrifuge. Viral titers were measured from the supernatants by the
end-point dilution method.
Attachment to cells.
LLC Mk2 cells on 24-well
plates were washed with DPBS and then incubated for 2 h under 50 µl of blocking buffer. Purified 35S-labeled virus was
added in 40 µl of blocking buffer, in four parallel wells for each
virus. The plates were incubated for 12 h at 4°C and then washed
twice with DPBS. The cells were lysed with 100 µl of 0.3 N NaOH and
agitated for 30 min at 37°C. Radioactivity was measured from these
samples in a MicroBeta counter (Wallac, Espoo, Finland), using 50-µl
samples and 200 µl of Optiphase Supermix SC/9235/21 scintillation
liquid (Wallac).
Uncoating kinetics.
LLC Mk2 cells on six-well
plates were washed with DPBS. About 106 cpm of labeled
virus (MOI, approximately 1) was incubated on the cells for 1 h at
18°C, after which the inoculum was removed, the cells were washed
twice with DPBS, and 2 ml of prewarmed (37°C) medium was added. The
infection was allowed to proceed for 0 to 3 h at 37°C, and the
plates were moved onto ice. The medium was collected, and the cells
were washed twice with cold DPBS. The cells were lysed by adding 200 µl of lysis buffer, and cell debris was removed by centrifuging for 2 min in an Eppendorf centrifuge. Sodium dodecyl sulfate (SDS) was added
in the supernatant to a final concentration of 0.2%, and sedimentation
of the virus particles was analyzed by centrifuging on a 15 to 30%
sucrose gradient at 38,000 rpm for 1 h 40 min (Beckman SW40 rotor;
18°C). Fractions of 200 µl were collected from the top, and the
radioactivity was measured as described above.
Spontaneous disintegration of viruses.
Purified
35S-labeled virus was diluted in minimal essential medium
containing 1% fetal calf serum to a final volume of 270 µl, and the
samples were incubated for either 0, 1, 3, 6, 24, or 72 h at
37°C. From the samples, 20 µl was used in measuring the viral titers, and 250 µl was used to assess the different particle forms by
centrifuging on a 15 to 30% sucrose gradient at 38,000 rpm for 1 h 40 min (Beckman SW40 rotor; 4°C). Fractions of 270 µl were
collected from the top, and the radioactivity was measured as described above.
Protein synthesis.
LLC Mk2 cells in 24-well
plates were infected with standard titers of wild-type and mutant
viruses. The cells were incubated for 30 min at room temperature and 30 min at 37°C, after which the virus was replaced by 1.5 ml of medium
without methionine. At various time points (3, 4, 5, 6, and 7 h
postinfection [hpi]), 5 µl (71.5 µCi total radioactivity) of
35S-Pro-Mix (Amersham Pharmacia Biotech, Little Chalfont,
United Kingdom) was added in the medium. Infection was allowed to
proceed for 30 min, after which the medium was discarded and the cells were lysed by adding 50 µl of 0.5% NP-40 in PBS. Cell debris was removed by centrifuging the samples for 5 min in an Eppendorf centrifuge. SDS was added to a final concentration of 1%. Protein production was assayed by SDS-polyacrylamide gel electrophoresis (PAGE), followed by blotting on a Hybond ECL nitrocellulose membrane (Amersham Pharmacia Biotech) and immunostaining with the polyclonal antibody 861 against CAV9 capsid proteins. Relative protein quantities were estimated by measuring the integrated optical densities of the
bands and comparing the integrated optical density values to those from
a standard curve. The reliability of immunostaining as a
semiquantitative measure of protein concentrations was confirmed by
comparing the autoradiography band densities with the immunostained bands.
Assembly intermediates.
LLC Mk2 cells in
six-well plates were infected with wild-type and mutant viruses as
described above. At 3.5 hpi, 5 µl (71.5 µCi) of
35S-Pro-Mix (Amersham) was added in the medium. At 4.5 hpi,
the radioactively labeled medium was replaced by regular medium. The cells were lysed at 4.5, 5.5, or 6.5 hpi with 400 µl of cold RSB containing 0.5% NP-40. Cell debris was removed by centrifuging 5 min
in an Eppendorf centrifuge. Assembly intermediates were analyzed by
centrifuging the supernatants at 38,000 rpm (Beckman SW40 rotor; 4°C)
either for 16 h on a 5 to 20% sucrose gradient in RSB or for
2.5 h on a 15 to 30% sucrose gradient in RSB. Fractions of 270 µl were collected from the top, and the radioactivity was measured.
The protein composition of the peak fractions was analyzed by SDS-PAGE.
After electrophoresis, the proteins were blotted on a Hybond ECL
nitrocellulose membrane (Amersham Pharmacia Biotech) and immunostained
using the polyclonal antibody 861 against CAV9 capsid proteins.
Survival in competition.
We carried out a competition study
of six mutants and the wild-type virus by performing five blind
passages of a mixture of the viruses on six-well plates of LLC
Mk2 cells. In addition to the mutants described in detail
in this article, the mixture contained the mutant A30N, initially
characterized as having similar properties to those of V34A. The
experiment was begun by infecting the cells simultaneously with an MOI
of 0.1 for each of the viruses. Infection was allowed to proceed in
four parallel wells at 37 or 32°C until full cytopathogenic effect
was seen after 2 or 3 days. The medium was collected and centrifuged in
an Eppendorf centrifuge to remove cells and cell debris, and a 1:100
dilution of the supernatant was used to infect the next set of cells.
After five passages, plaque titration was performed, and well-isolated
plaques were collected in 2 µl of medium. The sequences in the
mutated region were determined as described above, using primers 7625 and 9354.
Immunoprecipitation.
Radioactively labeled virus samples (10 µl; 10 000 cpm; [35S]methionine) were mixed with 10 µl of peptide antiserum 910 (26), either undiluted or in
10
1 or 10
2 dilutions. The mixture was
agitated for 2 h at room temperature, after which 1 ml of
Pansorbin (Calbiochem, San Diego, Calif.) (10
1 dilution
in DPBS containing 0.1% BSA) was added, and agitation was continued
for 30 min at room temperature. The precipitate was removed by 1 min of
centrifugation in an Eppendorf centrifuge. The unprecipitated
radioactivity was measured from 50 µl of supernatant as described
above. The precipitate was washed twice with washing buffer 1 and once
with washing buffer 2, and it was dissolved in 70 µl of 2% SDS-2%
-mercaptoethanol and heated for 5 min at 100°C. It was centrifuged
for 1 min in an Eppendorf centrifuge, and radioactivity was measured
from the supernatant as described above.
Molecular graphics.
In visualizing the molecular structures,
we used the RasMol 2.6 Molecular Visualisation Program by Roger Sayle,
Glaxo Wellcome Research and Development, Stevenage, Hertfordshire,
United Kingdom.
 |
RESULTS |
From a larger set of mutants, we selected five mutants that
covered as wide a range of properties as possible, judging from the
preliminary characterization. These mutants were then studied in more
detail in comparison with the wild-type CAV9. Each of the selected
mutants had one of the following amino acid substitutions in VP1: A30G,
A30S, T32S, V34A, and V34I. The mutant viruses are hereafter referred
to by using these codes only.
Production of infectious virus.
We studied the kinetics of
producing infectious virus at 32 and 37°C. The results indicate that
the kinetics appears identical for all the viruses (Fig.
1), reaching the plateau phase after 7 to
8 h at 37°C and after 12 h at 32°C. At 37°C, the
wild-type virus produces highest amounts of virus, with the mutants
A30S and V34I being almost as efficient. At 32°C, all mutants except for T32S produce more progeny virus than the wild type.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 1.
Kinetics of production of infectious progeny virus at
37°C (top) and 32°C (bottom). To clarify the picture, the growth
curves are shown as increase in titers after the attachment and washing
steps.
|
|
Efficiency of attachment to cells.
The wild-type CAV9 was
found to be most efficient in attaching to LLC cells, but A30S, T32S,
and V34I were almost as effective (Fig.
2). These differences are within the
error margin. In each of these cases, 18 to 20 % of the radioactive
label bound to cells. In contrast to these viruses, only 12% of A30G
and 7% of V34A attached to the cells.

View larger version (71K):
[in this window]
[in a new window]
|
FIG. 2.
Efficiency of attachment of CAV9 mutants to LLC
Mk2 cells. The results shown are averages from four
parallel experiments, and error bars indicate standard deviations.
|
|
Kinetics of formation of subviral particles.
The irreversible
shift from the native virion sedimenting at 160S to the altered virus
particle sedimenting at 135S is a measure that is frequently used in
assaying the uncoating of enteroviruses, although the role of the 135S
particle as an intermediate in infection has been questioned
(9). We assayed the relative amounts of 160S, 135S, and
80S particles after incubating cell-bound virus with cells at 37°C
for 0, 1, or 3 h. Formation of subviral particles was clearly
faster for A30G and V34A, compared to the other mutants or the
wild-type, and the alteration to 135S particles was almost quantitative
already after 1 h (Fig. 3).
Alteration of A30S and V34I was somewhat more efficient than that of
the wild-type, while T32S showed a reduced rate of alteration. In none
of the cases was faster uncoating found to accelerate the subsequent
steps in infection.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 3.
Sedimentation analysis of CAV9 uncoating after
incubating cell-bound virus for 0, 1, or 3 h at 37°C. Prior to
this incubation, 35S-labeled viruses (about 2.5 × 106 cpm) were allowed to adsorb to cells for 2 h at
18°C. Percentages of total label forming each peak (160S, 135S, and
80S) are shown.
|
|
Spontaneous disintegration of virions.
Two of the mutant
viruses, A30G and V34A, turned out to be extremely unstable. Already
after an incubation of 1 h at 37°C in the regular growth medium,
the majority of these virus particles were sedimenting at 135S instead
of 160S. Two other mutants, A30S and V34I, were only slightly less
stable than the wild-type virus. The 160S particles of these three
viruses had half-lives of approximately 3 to 4 h. In contrast,
T32S turned out to be significantly more stable, having a half-life of
almost 24 h. These results are shown in Fig.
4. The disintegration of the virus
particles was also seen as a decrease in viral titers, as is shown in
Fig. 5. Differences seen between A30G and
V34A are negligible, as are also differences between the rest of the
viruses before the final time point at 72 h. It appears that for
all the viruses, the decrease in infectious units occurs in three
separate phases. The first phase is fast, occurring during the first 3 or 6 h. After this point, the decrease is significantly slower
until at least the time point of 24 h, being accelerated again
before the time point of 72 h. It was surprising that the
wild-type virus was found to disintegrate spontaneously already in a
few hours.

View larger version (52K):
[in this window]
[in a new window]
|
FIG. 4.
Sedimentation analysis of spontaneous formation of
subviral particles in medium. Percentages of total label as in the
legend to Fig. 3 are shown.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 5.
Decrease of viral titers after incubation of 3, 6, 24, or 72 h in regular medium at 37°C. The results shown are
averages of four parallel dilution series, comprising a total of 24 cell wells per dilution.
|
|
Particle/infectious unit ratio.
We used purified viruses,
sedimenting at 160S, with known relative protein contents that were
adjusted on the standard curve (Materials and Methods) for maximal
accuracy of concentration determination. Aliquots of the samples were
used in determining the amounts of VP1, as described in Materials
and Methods, and in measuring the viral titers. Relative ratios of
virus particle to infectious unit were calculated from these two
parameters. All the mutants were found to have higher
particle/infectious unit ratios than the wild-type. A30S, T32S, and
V34I were moderately reduced, whereas A30G and V34A had only 2 and 4%
of the infectivity of the wild-type (Table
2). The numbers given are unavoidably imprecise due to the inaccuracies in both methods used in quantitation.
Survival in competition.
When the viruses had to compete
against each others, three different viruses were found to survive at
both temperatures. At 37°C, when sequencing 45 plaques isolated after
five passages of four parallel passaging chains, the wild-type was
found to survive in addition to A30S and V34I. These viruses also had
the largest plaque sizes, and the stabilities of the two mutants were similar to that of the wild-type. At 32°C, the wild-type virus was
not found among the 45 viruses recovered, but rather only mutants A30G,
A30N, and A30S were found. The last one of these is thus the only one
surviving at both temperatures, presumably due to properties that are
close to wild type, but with the capsid being slightly less stable.
These results are completely in accordance with the kinetics of
producing infectious virus (Fig. 1).
Plaque phenotypes.
Plaque assays were performed at 32, 37, and
41°C. The plaque phenotypes are shown in Fig.
6. At the two higher temperatures, the
wild-type virus had the largest plaque sizes, whereas at 32°C it was
among the poorest ones. The two unstable mutants, A30G and V34A, had a
clear advantage at the decreased temperature, having very small plaque
sizes at 37 and 41°C. The intermediate ones, A30S and V34I, had only
slightly reduced plaque sizes at both these temperatures, while at
32°C they had some advantage over the wild-type. The most surprising
plaque phenotype was seen in the T32S mutant. It had moderately reduced
plaque sizes at 37°C but very small plaques at both 32 and 41°C,
indicating a very narrow optimum temperature for infection.
Immunoprecipitation.
To study whether the mobility of the
N-terminal extension was changed due to the mutations, we performed an
immunoprecipitation experiment using antiserum 910, which is a peptide
antiserum raised against the peptide KEVPALTAVETGATC (26).
This antiserum has been shown to recognize peptides corresponding to
the CAV9 VP1 sequence ASVPALTAVETGHT and single amino acid
modifications of this peptide, corresponding to mutations A30G, A30S,
T32S, and V34A (Taina Härkönen, unpublished results). The
peptide corresponding to V34I has not been studied. Both of the Ala30
mutants were precipitated by the antiserum 910 similarly or even better
than the wild-type CAV9 (Fig. 7). Both of
the Val34 mutants were also precipitated by this antiserum, but to a
lower degree than the wild type. In contrast, precipitation of the T32S
mutant was nearly abolished.
Unaltered properties.
We found no differences in the time
scale of infection, protein synthesis, accumulation of assembly
intermediates, or release from cells. In all cases, measurable
concentrations of protein were synthesized within 3 to 4 h pi, and
the peak concentrations were reached after 7 h. There were no
differences in the accumulation patterns of particles sedimenting at
approximately 15S, 80S, or 160S (presumably pentamers, empty capsids,
and mature virions, respectively), and PAGE analysis showed that
maturation cleavage occurs normally. Release of virus from cells was
unaltered, judging by viral titers inside or outside cells at various
time points. Maximum titers were reached at approximately 7 hpi (in
cells) or 9 hpi (in media).
 |
DISCUSSION |
We have shown that mutations in the conserved PALTAVETGHT
region of the capsid protein VP1 of CAV9 result in defects in producing infectious progeny virus. The differences between the viruses were
found in six different parameters: (i) attachment to cells, (ii)
uncoating, (iii) stability of the virions, (iv) particle/infectious unit ratio, (v) production of infectious progeny virus, and (vi) immunoprecipitation. All these phenomena can be explained by the observed variation in capsid stability.
Stability and uncoating.
The particle/infectious unit ratios
and the capability of the viruses to produce infectious progeny were in
complete accordance with the differences observed in stability,
allowing the conclusion that nonspecific, and thereby nonproductive,
conversion to the 135S form of the mutant viruses resulted in
accumulation of noninfectious particles (most notably, A30G and V34A)
or hindered initiation of infection (T32S). The two opposing effects,
the uncoating that is triggered either too easily or ineffectively,
reflect the two requirements that the virus capsid must meet:
protection of the RNA and the capacity to uncoat upon binding to a
susceptible cell.
The stability of T32S appears to reflect a decrease in mobility of the
N-terminal extension of VP1. Unlike the other mutants, the amino acid
sequence of this mutant was recognized only as a peptide but not in a
virus sample, which suggests, but does not prove, that the studied
motif is less dynamic in T32S than it is in the wild-type virion. An
alternative explanation is that the epitope is recognized as a peptide,
but not in the conformation seen in the virus. The other studied mutant
sequences were recognized both as peptides and in virus samples. It is
noteworthy that the enhanced uncoating did not give any measurable
advantage to any of the mutant viruses, even though the 160S forms
could be purified and three of the five mutants attached to cells to a
similar degree with the wild-type virus. It therefore appears that
although the mutants are capable of correct uncoating, they perform it
in a hasty and nonspecific manner, many of the virions being
irreversibly converted into 135S particles before getting the correct
signal to initiate uncoating, thereby becoming noninfectious. The fact that a considerable proportion of virions are still found in the native
form after 3 h of incubation at 37°C after binding to cell demonstrates the high particle/infectious unit ratio that is common to
enteroviruses and suggests that a significant proportion of the bound
viruses may have nonspecific interactions with the cell. This would be
consistent with the finding that the proportion of the unaltered 160S
form becomes clearly smaller for the labile mutants both in the
presence and in the absence of cells (Fig. 3 and 4). It appears that
uncoating is efficiently triggered upon meeting the correct conditions,
which is not merely binding to cells, and easing the uncoating step per
se will not necessarily give any advantage to the virus.
Differences in the attachment step are unlikely to explain the altered
properties of the mutants. Attachment to cells was very close to equal
for all viruses except for the two highly unstable mutants, A30G and
V34A. On the other hand, it is known that 135S particles of poliovirus
are incapable of or extremely inefficient at (8) binding
to cells and initiating infection. Moreover, the differences in
attachment efficiencies were merely threefold at most, whereas
differences in infectivity were more than 1 log. It therefore seems
safe to assume that differences in attachment to cells did not have a
major role in the defects found in the mutants.
Role and topology of the VP1 N terminal extension.
In all
enteroviruses, the whole VP1 N terminal extension is an integral part
of the stabilizing network of intraprotomer, intrapentamer, and
interpentamer interactions that occur on the inner surface of the
capsid. In the poliovirus empty capsid (VP0, VP1, VP3), the N-terminal
67 amino acids of VP1 are disordered (4). The stabilizing
network, formed as a consequence of the maturation cleavage and/or the
presence of RNA, then serves by locking the capsid into the stable
form. The three-dimensional structure of CAV9 was recently published
(14), including a detailed model of the VP1 N terminus.
The N-terminal 12 amino acids form a finger pointing towards the base
of the fivefold axis. At position His13, the chain comes into close
contact with Ser58 of the same chain. Together the residues 13 to 58 form a loop structure that extends towards the threefold axis facing
the interior of the virion, with residues Pro29 to Thr47 forming a
hook-like structure, diving into a cavity formed by the three other
capsid proteins. The base of the cavity is formed by the BIDG
-sheet
of the VP3, the tip of the cavity is formed by the VP2, and it is
loosely covered by the C-terminal 16 amino acids of the VP4. This
structure repeats in the seven known enterovirus structures and the
four rhinovirus structures, with the exceptions that in rhinoviruses 1A
and 16, the parts of VP2 and VP4 that could cover the hook are not seen
in the structure. The exceptions may reflect the conformational
flexibility of the capsid that is required in externalization of the
VP4 and the N terminus of VP1. In the hook region, 7 of 24 amino acids
(Pro29, Leu31, Ala33, Glu35, Gly37, Thr50, and Arg51) showed no
variation in an alignment of 79 different enterovirus sequences, and
when trying to mutate Leu31, we could recover no viable mutant viruses,
except for the ones with different leucine codons (2).
Five of the completely conserved amino acids are in the PALTAVETGHT
motif, which is the region covered by VP4 at the tip of the hook.
Conserved intraprotomer contact points.
We mapped the close
contacts that the PALTAVETGHT motif has with the other capsid proteins
(connected Van der Waals surfaces) and found that there are several
contact points that are identical in all known enterovirus structures
(10, 11, 14, 15, 19, 24, 29), and these are mostly
conserved in rhinoviruses as well (3, 13, 18, 31). In
CAV9, these contact points are at the following positions:
VP1/Leu31-VP3/Gln161, VP1/Leu31-VP3/Ser163, VP1/Thr32-VP3/Ser163,
VP1/Glu35-VP3/Ser162, VP1/Gly37-VP2/His187, and
VP1/Thr39-VP4/Thr54 (Fig. 8). All capsid
proteins are involved in these interactions.

View larger version (71K):
[in this window]
[in a new window]
|
FIG. 8.
(A) Location of the VP1 hook in the three-dimensional
structure of one protomer of CAV9, seen from the inside of the capsid.
The tip of the hook dives in a cavity, the base of which is formed by
the capsid proteins VP2 and VP3. The N termini of VP1, VP3, and VP4 are
extended toward the fivefold axis at the bottom right. VP1, VP2, and
VP3 are shown as space-filling models, while VP4 is shown as backbone
only. The PALTAVETGHT motif is shown in cyan, while the rest of VP1 is
blue. VP2, VP3, and VP4 are shown in yellow, red, and green,
respectively. (B) A close view of the PALTAVETGHT motif and its
surroundings in CAV9. Intraprotomer contact points that are completely
conserved among PV1, PV2, PV3, CAV9, CBV5, echovirus 1, and BEV are
shown as ball-and-stick models with dotted Van der Waals surfaces. The
intertwined connection between the conserved VP3 amino acids 161 to 163 and VP1 amino acids 31 to 35 may have an important stabilizing role.
Yellow text and arrows indicate the conserved amino acids, and white
text and arrows indicate the amino acid chains included in this figure.
Alpha carbons of conserved residues are colored white. CAV9 coordinates
were from the Protein Data Bank of the Research Collaboratory for
Structural Bioinformatics (available at http://www.rcsb.org/pdb/).
|
|
In a study by Mosser and coworkers (23), the uncoating
inhibitor WIN 51711 was used to select drug-resistant mutants of PV3/Sabin. Out of the 13 drug-resistant mutants, 7 were drug dependent, and these were all found to have single amino acid substitutions near
Thr53 of the VP4. One of the seven mutations was alanine in place of
Thr53 of the VP4, and three of them were mutations of the three amino
acids surrounding, but not including, Thr50 of VP1 (Table
3).. Thr53 of VP4 and Thr50 of VP1 form
one of the completely conserved contacts in enterovirus and rhinovirus structures. All the drug-dependent mutants were reported to be hyperlabile without the presence of WIN 51711, displaying half-lives of
less than 1 min in the absence of drug. This resembles the two labile
mutants described here, the mutants A30G and A34V, and suggests that
some of the mutations in the site saturation mutagenesis study, from
which our collection of mutants originate, might also have been
hyperlabile and, as such, were excluded from the viable ones.
Molecular basis for labilization or stabilization.
The methyl
group of Ala30 of VP1 has hydrophobic contacts with Ile154 and Val165
of VP3. It appears that these contacts contribute to the virion
stability since replacing alanine with glycine (A30G) drastically
labilizes the virion. On the other hand, the additional hydroxyl group
of a substitutive serine is much less detrimental to the virus (A30S).
There is plenty of space for this position, and an even larger side
chain could easily be fitted in the gap between VP1 and VP3. In fact,
even glutamine, asparagine, and leucine have been found in this
position of CAV9 (2). In PV1, a mutation at this position
(A43V) was found to result in neurovirulence in mice (7).
Earlier, mouse neurovirulence had also been associated with mutations
that are at positions
2 and +2 (E40G, P54S) relative to the
PALTAVETGAT motif in PV2 (22). In both studies,
neurovirulence was suggested to be due to facilitated conformational
changes during early steps of mouse nerve cell infection. Curiously,
two different Ala54 mutations, A54T and A54V (at position +4 relative to PALTAVETGAT), resulted in suppression of the temperature-sensitive (ts) phenotype of PV3 (21) (Table 3).
Both methyl groups of VP1 Val34 have hydrophobic interactions with
Trp189 of VP2. In addition, it has weaker contacts with VP3 amino acids
Phe213, Ser163, and Thr117, and the carboxyl oxygen makes a hydrogen
bond to Gly37 nitrogen. The VP1 Val34 is in a densely packed region,
and any additional mass would have to replace some of the elements
mentioned above. Isoleucine was the largest substitutive amino acid
found at this position, and the highly labile nature of the V34I mutant
may thus be due to structural constraints that distort the stabilizing
network on the capsid inner surface. The alanine of the mutant V34A
lacks some of the hydrophobic contacts that the wild-type valine has,
which may result in the less pronounced labilization observed.
Thr32 of VP1 has a conserved contact with Ser163 of VP3. The side chain
of VP1 Thr32 is on the inside of the loop forming the hook, directly
facing Ser40 of the same chain. The side chain methyl of Thr32 is in
contact with the Ser163 side chain, while the hydroxyl group is not
close to other amino acid residues. It appears that the stabilizing
effect of the T32S mutation, which removes the methyl of the side
chain, might result from the hydroxyl group contacting either VP3
Ser163 or, in a more extended conformation, VP1 Ser40. Water molecules
may participate in these interactions. A contact that would be parallel
to the Ser32-Ser40 contact in the CAV9 mutant, is seen in bovine
enterovirus (BEV). In BEV, there is a glutamine (Gln39) at the position
corresponding to Thr32 of CAV9, having close interactions with the
polar side chains of Ser47 (corresponding to Ser40 of CAV9) and Thr48
of the same chain. It seems plausible that this contact has been
selected in its structural context to stabilize the BEV structure. The increased stability and reduced infectivity of T32S show that an
optimal sequence here does not have maximal binding to the cavity, but
the balance between stability and mobility must be maintained.
Conclusions.
The hook region of VP1 and the part of VP4
covering it are disordered in the poliovirus empty capsid
(4). Formation of the interactions on the capsid inner
surface stabilizes the capsid into the mature, metastable form and
increases the thermal energy required for uncoating. It seems that the
PALTAVETGHT mutants are not affected in their capability to assemble
into mature virions. Instead, mutations in this motif decrease the
potential energy barrier for uncoating, by preventing the capsid from
descending into the minimal energy state.
In view of the conserved contacts between the PALTAVETGHT motif and
the other capsid proteins, it is intriguing that this region is known
to be so highly dynamic in nature. As we have shown earlier, the
periodic hydrophobicity profile of the studied motif could not be
changed in a site saturation mutagenesis study, as none of the viable
mutants had a polar amino acid replaced by a nonpolar one, or vice
versa (2). Then, the mutants that were already selected by
their viability had deteriorated properties that were connected with
either labilized or stabilized phenotypes. The result that a single
mutation in the VP4 side of one of the conserved contact points
resulted in a hyperlabile phenotype of poliovirus (23)
further underlines the connection between the PALTAVETGHT motif and the
cavity. We therefore suggest that the VP1 hook, being held in the
VP2-VP3 depression by a VP4 cover, has a decisive role in initiating
the viral uncoating.
 |
ACKNOWLEDGMENTS |
This study was supported by grants from the Academy of Finland,
the Sigrid Juselius Foundation, and the Finnish National Technology Agency (TEKES).
We are grateful for the skillful technical assistance of Pekka
Mäntyvaara, Anita Hartikainen, Noora Alakulppi, and Mervi Eskelinen and for expert advice from Mick Mulders and Glyn Stanway.
 |
FOOTNOTES |
*
Corresponding author. Present address: Centro de
Biología Molecular "Severo Ochoa," Universidad Autonoma de
Madrid, 28049 Madrid, Spain. Phone: (34-91) 3978 477. Fax: (34-91) 3974 799. E-mail: airaksinen{at}cbm.uam.es.
 |
REFERENCES |
| 1.
|
Airaksinen, A., and T. Hovi.
1998.
Modified base compositions at degenerate positions of a mutagenic oligonucleotide enhance randomness in site-saturation mutagenesis.
Nucleic Acids Res.
26:576-581[Abstract/Free Full Text].
|
| 2.
|
Airaksinen, A.,
M. Roivainen,
G. Stanway, and T. Hovi.
1999.
Site-saturation mutagenesis of the PALTAVETG motif in coxsackievirus A9 capsid protein VP1 reveals evidence of conservation of a periodic hydrophobicity profile.
J. Gen. Virol.
80:1919-1927[Abstract/Free Full Text].
|
| 3.
|
Arnold, E., and M. G. Rossmann.
1988.
The use of molecular-replacement phases for the refinement of the human rhinovirus 14 structure.
Acta Crystallogr. A
44:270-282.
|
| 4.
|
Basavappa, R.,
R. Syed,
O. Flore,
J. P. Icenogle,
D. J. Filman, and J. M. Hogle.
1994.
Role and mechanism of the maturation cleavage of VP0 in poliovirus assembly: structure of the empty capsid assembly intermediate at 2.9 Å resolution.
Protein Sci.
3:1651-1669[Abstract].
|
| 5.
|
Belnap, D. M.,
D. J. Filman,
B. L. Trus,
N. Cheng,
F. P. Booy,
J. F. Conway,
S. Curry,
C. N. Hiremath,
S. K. Tsang,
A. C. Steven, and J. M. Hogle.
2000.
Molecular tectonic model of virus structural transitions: the putative cell entry states of poliovirus.
J. Virol.
74:1342-1354[Abstract/Free Full Text].
|
| 6.
|
Chang, K. H.,
P. Auvinen,
T. Hyypiä, and G. Stanway.
1989.
The nucleotide sequence of coxsackievirus A9; implications for receptor binding and enterovirus classification.
J. Gen. Virol.
70:3269-3280[Abstract/Free Full Text].
|
| 7.
|
Couderc, T.,
N. Guédo,
V. Calvez,
I. Pelletier,
J. Hogle,
F. Colbère-Garapin, and B. Blondel.
1994.
Substitutions in the capsids of poliovirus mutants selected in human neuroblastoma cells confer on the Mahoney type 1 strain a phenotype neurovirulent in mice.
J. Virol.
68:8386-8391[Abstract/Free Full Text].
|
| 8.
|
Curry, S.,
M. Chow, and J. M. Hogle.
1996.
The poliovirus 135S particle is infectious.
J. Virol.
70:7125-7131[Abstract/Free Full Text].
|
| 9.
|
Dove, A. W., and V. R. Racaniello.
1997.
Cold-adapted poliovirus mutants bypass a postentry replication block.
J. Virol.
71:4728-4735[Abstract].
|
| 10.
|
Filman, D. J.,
R. Syed,
M. Chow,
A. J. Macadam,
P. D. Minor, and J. M. Hogle.
1989.
Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus.
EMBO J.
8:1567-1579[Medline].
|
| 11.
|
Filman, D. J.,
M. W. Wien,
J. A. Cunningham,
J. M. Bergelson, and J. M. Hogle.
1998.
Structure determination of echovirus 1.
Acta Crystallogr. D Biol. Crystallogr.
54:1261-72[CrossRef][Medline].
|
| 12.
|
Fricks, C. E., and J. M. Hogle.
1990.
Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding.
J. Virol.
64:1934-1945[Abstract/Free Full Text].
|
| 13.
|
Hadfield, A. T.,
W. M. Lee,
R. Zhao,
M. A. Oliveira,
I. Minor,
R. R. Rueckert, and M. G. Rossmann.
1997.
The refined structure of human rhinovirus 16 at 2.15 A resolution: implications for the viral life cycle.
Structure
5:427-421[Medline].
|
| 14.
|
Hendry, E.,
H. Hatanaka,
E. Fry,
M. Smyth,
J. Tate,
G. Stanway,
J. Santti,
M. Maaronen,
T. Hyypiä, and D. Stuart.
1999.
The crystal structure of coxsackievirus A9: new insights into the uncoating mechanisms of enteroviruses.
Structure
7:1527-1538[Medline].
|
| 15.
|
Hogle, J. M.,
M. Chow, and D. J. Filman.
1985.
Three-dimensional structure of poliovirus at 2.9 Å resolution.
Science
229:1358-1365[Abstract/Free Full Text].
|
| 16.
|
Hovi, T., and M. Roivainen.
1993.
Peptide antisera targeted to a conserved sequence in poliovirus capsid VP1 cross-react widely with members of the genus Enterovirus.
J. Clin. Microbiol.
31:1083-1087[Abstract/Free Full Text].
|
| 17.
|
Hughes, P. J.,
C. Horsnell,
T. Hyypiä, and G. Stanway.
1995.
The coxsackievirus A9 RGD motif is not essential for virus viability.
J. Virol.
69:8035-8040[Abstract].
|
| 18.
|
Kim, S. S.,
T. J. Smith,
M. S. Chapman,
M. G. Rossmann,
D. C. Pevear,
F. J. Dutko,
P. J. Felock,
G. D. Diana, and M. A. McKinlay.
1989.
Crystal structure of human rhinovirus serotype 1A (HRV1A).
J. Mol. Biol.
210:91-111[CrossRef][Medline].
|
| 19.
|
Lentz, K. N.,
A. D. Smith,
S. C. Geisler,
S. Cox,
P. Buontempo,
A. Skelton,
J. DeMartino,
E. Rozhon,
J. Schwartz,
V. Girijavallabhan,
J. O'Connell, and E. Arnold.
1997.
Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological properties of three poliovirus serotypes.
Structure
5:961-978[Medline].
|
| 20.
|
Li, Q.,
A. Gomez Yafal,
Y. Mie-Ha Lee,
J. Hogle, and M. Chow.
1994.
Poliovirus neutralization by antibodies to internal epitopes of VP4 and VP1 results from reversible exposure of these sequences at physiological temperature.
J. Virol.
68:3965-3970[Abstract/Free Full Text].
|
| 21.
|
Macadam, A. J.,
C. Arnold,
J. Howlett,
A. John,
S. Marsden,
F. Taffs,
P. Reeve,
N. Hamada,
K. Wareham,
J. Almond,
N. Cammack, and P. D. Minor.
1989.
Reversion of the attenuated and temperature-sensitive Phenotypes of the Sabin type 3 strain of poliovirus in vaccinees.
Virology
172:408-414[CrossRef][Medline].
|
| 22.
|
Moss, E. G., and V. R. Racaniello.
1991.
Host range determinants located on the interior of the poliovirus capsid.
EMBO J.
10:1067-1074[Medline].
|
| 23.
|
Mosser, A. G.,
J.-Y. Sgro, and R. R. Rueckert.
1994.
Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions.
J. Virol.
68:8193-8201[Abstract/Free Full Text].
|
| 24.
|
Muckelbauer, J. K.,
M. Kremer,
I. Minor,
G. Diana,
F. J. Dutko,
J. Groarke,
D. C. Pevear, and M. G. Rossmann.
1995.
The structure of coxsackievirus B3 at 3.5 Å resolution.
Structure
3:653-667.
|
| 25.
|
Roivainen, M.,
T. Hyypiä,
L. Piirainen,
N. Kalkkinen,
G. Stanway, and T. Hovi.
1991.
RGD-dependent entry of coxsackievirus A9 into host cells and its bypass after cleavage of VP1 protein by intestinal proteases.
J. Virol.
65:4735-4740[Abstract/Free Full Text].
|
| 26.
|
Roivainen, M.,
L. Piirainen,
T. Rysä,
A. Närvänen, and T. Hovi.
1993.
An immunodominant N-terminal region of VP1 protein of poliovirion that is buried in crystal structure can be exposed in solution.
Virology
195:762-765[CrossRef][Medline].
|
| 27.
|
Roivainen, M.,
L. Piirainen,
T. Hovi,
I. Virtanen,
T. Riikonen,
J. Heino, and T. Hyypiä.
1994.
Entry of coxsackievirus A9 into host cells: specific interactions with v 3 integrin, the vitronectin receptor.
Virology
203:357-365[CrossRef][Medline].
|
| 28.
|
Roivainen, M.,
L. Piirainen, and T. Hovi.
1996.
Efficient RGD-independent entry process of coxsackievirus A9.
Arch. Virol.
141:1909-1919[CrossRef][Medline].
|
| 29.
|
Smyth, M.,
J. Tate,
E. Hoey,
C. Lyons,
S. Martin, and D. Stuart.
1995.
Implications for viral uncoating from the structure of bovine enterovirus.
Nat. Struct. Biol.
2:224-31[CrossRef][Medline].
|
| 30.
|
Tosteson, M. T., and M. Chow.
1997.
Characterization of the ion channels formed by poliovirus in planar lipid membranes.
J. Virol.
71:507-511[Abstract].
|
| 31.
|
Zhao, R.,
D. C. Pevear,
M. J. Kremer,
V. L. Giranda,
J. A. Kofron,
R. J. Kuhn, and M. G. Rossmann.
1996.
Human rhinovirus 3 at 3.0 A resolution.
Structure
4:1205-1220[Medline].
|
Journal of Virology, January 2001, p. 952-960, Vol. 75, No. 2
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.2.952-960.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Mateo, R., Mateu, M. G.
(2007). Deterministic, Compensatory Mutational Events in the Capsid of Foot-and-Mouth Disease Virus in Response to the Introduction of Mutations Found in Viruses from Persistent Infections. J. Virol.
81: 1879-1887
[Abstract]
[Full Text]
-
Laine, P., Blomqvist, S., Savolainen, C., Andries, K., Hovi, T.
(2006). Alignment of capsid protein VP1 sequences of all human rhinovirus prototype strains: conserved motifs and functional domains. J. Gen. Virol.
87: 129-138
[Abstract]
[Full Text]